Skip to main content
Industry News
Roche plans trial for Actemra as COVID-19 treatment

Roche has secured FDA approval to launch a late-stage trial by early April to assess the efficacy of its drug Actemra, or tocilizumab, in critically ill patients with COVID-19 who are hospitalized with pneumonia. China approved use of the interleukin-6 inhibitor to treat COVID-19 patients with severe lung damage who have elevated IL-6 levels in the blood.

Full Story: